The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure on the pharma giant’s injectable Rybrevant in non-small cell lung cancer.

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by blinded independent central review in newly diagnosed EGFR exon 20 insertion ...

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.